3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
21
Leukemia, Myeloid, Acute
21
Congenital Abnormalities
14
Lymphoma, Non-Hodgkin
12
Myelodysplastic Syndromes
11
Leukemia, Lymphocytic, Chronic, B-Cell
11
Leukemia
11
Hodgkin Disease
9
Multiple Myeloma
8
Lymphoma, Follicular
7
Lymphoma, B-Cell, Marginal Zone
7
Lymphoma
7
Leukemia, Myeloid, Accelerated Phase
7
Waldenstrom Macroglobulinemia
6
Lymphoma, Mantle-Cell
6
Lymphoma, Large B-Cell, Diffuse
6
Anemia, Refractory, with Excess of Blasts
6
Sezary Syndrome
5
Myeloproliferative Disorders
5
Mycosis Fungoides
5
Lymphoma, T-Cell, Cutaneous
5
Lymphoma, Large-Cell, Immunoblastic
5
Leukemia, Myelomonocytic, Chronic
5
Leukemia, Myeloid, Chronic-Phase
5
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
5
Hematologic Neoplasms
5
Graft vs Host Disease
5
Burkitt Lymphoma
5
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
4
Lymphoma, Extranodal NK-T-Cell
4
Interventions
blinatumomab
15
Cyclophosphamide
15
Cytarabine
14
Azacitidine
11
venetoclax
10
fludarabine
10
fludarabine phosphate
7
Methotrexate
7
Daunorubicin
7
Rituximab
6
Vincristine
5
Mercaptopurine
5
Whole-Body Irradiation
4
Melphalan
4
Idarubicin
4
Etoposide
4
Imatinib Mesylate
3
Granulocyte Colony-Stimulating Factor
3
Doxorubicin
3
Dexamethasone
3
Cladribine
3
Busulfan
3
Asparaginase
3
thymoglobulin
2
pembrolizumab
2
pegaspargase
2
nilotinib
2
midostaurin
2
daratumumab
2
Vindesine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm, Residual
×
Transplantation
×
Other hematologic neoplasm
×
Clear all
NCT07443592
2026-03-02
LAL-2025
PETHEMA Foundation
Phase NA
Not yet recruiting
330 enrolled